SCHEMBL29613330

SCHEMBL29613330

C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)[C@@H](C)O

nearest known ligand 0.45

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 1/20 0.45
▸ HASPIN Q8TF76 1/20 0.41
▸ NPY4R P50391 8/20 0.39
▸ NPY1R P25929 5/20 0.39
▸ NPY2R P49146 3/20 0.39
▸ NPY5R Q15761 3/20 0.39
▸ RAMP3 O60896 3/20 0.38
▸ CALCR P30988 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30563225 0.92 NOD1 (0.51) NOD1NPY4RNPY1RNPY2RNPY5R
SCHEMBL29740225 0.92 NOD1 (0.46) NOD1NPY4RNPY1RNPY2RNPY5R
SCHEMBL29540259 0.92 NOD1 (0.46) NOD1NPY4RNPY1RNPY2RNPY5R
SCHEMBL30321981 0.88 NOD1 (0.47) NOD1HASPINNPY4RNPY1RNPY2R
SCHEMBL16508552 0.88 SIRT2 (0.41) NPY4RNPY1RNPY2RNPY5RRAMP3
SCHEMBL5044651 0.87 NOD1 (0.47) NOD1HASPINNPY4RNPY1RNPY2R
SCHEMBL30855554 0.87 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5R
SCHEMBL29789057 0.87 NPY4R (0.50) NOD1NPY4RNPY1RNPY2RNPY5R
SCHEMBL23286096 0.87 NOD1 (0.50) NOD1NPY4RNPY1RNPY2RNPY5R
SCHEMBL1711608 0.87 NOD1 (0.50) NOD1NPY4RNPY1RNPY2RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594227-B2 Tetrapeptide and compositions comprising tetrapeptides THE BOOTS COMPANY PLC (GB) 2026-04-07 — — US disclosed
WO-2025215346-A1 SKIN WOUND TREATMENT THE BOOTS COMPANY PLC (GB) 2025-10-16 — — WO disclosed
WO-2025215347-A1 SKIN WOUND TREATMENT THE BOOTS COMPANY PLC (GB) 2025-10-16 — — WO disclosed
WO-2025215349-A1 HAIR GROWTH RESTORATION THE BOOTS COMPANY PLC (GB) 2025-10-16 — — WO disclosed
WO-2025215348-A1 SKIN WOUND TREATMENT THE BOOTS COMPANY PLC (GB) 2025-10-16 — — WO disclosed
EP-4631518-A1 COMPOSITIONS FOR TREATING DISEASES OF THE AIRWAYS The Boots Company plc (GB) 2025-10-15 — — EP disclosed
EP-4631517-A1 SKIN WOUND TREATMENT The Boots Company plc (GB) 2025-10-15 — — EP disclosed
US-20250170043-A1 KIT OF COSMETIC COMPOSITIONS THE BOOTS COMPANY PLC (GB) 2025-05-29 — — US disclosed
US-20250161200-A1 COSMETIC COMPOSITION COMPRISING EXTRACT OF OPHIOPOGON JAPONICUS AND AT LEAST ONE CERAMIDE THE BOOTS COMPANY PLC (GB) 2025-05-22 — — US disclosed
US-20250161201-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2025-05-22 — — US disclosed
EP-4140473-A1 COSMETIC COMPOSITIONS The Boots Company plc (GB) 2023-03-01 — — EP disclosed
WO-2022106054-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES THE BOOTS COMPANY PLC (GB) 2022-05-27 — — WO disclosed
WO-2022106055-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES THE BOOTS COMPANY PLC (GB) 2022-05-27 — — WO disclosed
WO-2022106056-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES THE BOOTS COMPANY PLC (GB) 2022-05-27 — — WO disclosed
WO-2022106057-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES THE BOOTS COMPANY PLC (GB) 2022-05-27 — — WO disclosed
EP-4000595-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES The Boots Company plc (GB) 2022-05-25 — — EP disclosed
EP-4000597-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES The Boots Company plc (GB) 2022-05-25 — — EP disclosed
EP-4000598-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES The Boots Company plc (GB) 2022-05-25 — — EP disclosed
EP-4000596-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES The Boots Company plc (GB) 2022-05-25 — — EP disclosed
EP-4001294-A1 TETRAPEPTIDE AND COMPOSITIONS COMPRISING TETRAPEPTIDES The Boots Company plc (GB) 2022-05-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12594227-B2 Tetrapeptide and compositions comprising tetrapeptides SRRM2, SGTA, QARS1 NOD1 2548/4885HASPIN 1386/4885NPY4R 992/4885
US-20250170043-A1 KIT OF COSMETIC COMPOSITIONS CHKA, CHKB, SGMS2 NOD1 3976/4885HASPIN 1140/4885NPY4R 4144/4885
US-20250161200-A1 COSMETIC COMPOSITION COMPRISING EXTRACT OF OPHIOPOGON JAPONICUS AND AT LEAST ONE CERAMIDE SGMS2, SGMS1, CERS2 NOD1 4809/4885HASPIN 1896/4885NPY4R 3867/4885
US-20250161201-A1 COSMETIC COMPOSITION CYP19A1, SHBG, HSD17B11 NOD1 4715/4885HASPIN 2170/4885NPY4R 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback